[{"from": "human", "value": "Could you provide a description of this molecule? [C][C@H1][C][C][Branch2][=Branch1][Branch1][N][Branch1][Ring2][C][Ring1][Branch1][C][=C][Branch2][Ring2][Ring1][C][=C][C][=Branch1][Ring2][=N][Ring1][=Branch1][N][C][=C][C][=Branch1][Ring2][=N][Ring1][Branch1][O][C][C][Branch1][C][C][Branch1][C][C][C][Branch1][C][F][Branch1][C][F][F][C][=Branch1][C][=O][N][S][=Branch1][C][=O][=Branch1][C][=O][C][=C][N][Branch1][=Branch1][N][=C][Ring1][Branch1][C][C][Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product TrikaftaTM. Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor. While dual corrector/potentiator combination therapy has proven useful in the treatment of a subset of CF patients, their use is typically limited to patients who are homozygous for the F508del-CFTR gene. Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for F508del-CFTR and a gene that does not produce protein or produces proteins unresponsive to ivacaftor or tezacaftor. The triple combination product TrikaftaTM, manufactured by Vertex Pharmaceuticals, is the first product approved for the treatment of CF in individuals who are either homo- or heterozygous for the F508del-CFTR  gene - this represents approximately 70-90% of all CF patients."}]